Cathie's Ark Logo
ARKK Holdings/EDIT/
Editas Medicine Inc Logo

ARKK Holdings of Editas Medicine (EDIT) - Updated Daily

TherapeuticsGene TherapyCAR-NK Gene TherapyCRSPR Gene Editing

Trades of EDIT Made In ARKK

Why do the number of shares of a company held in an ARK ETF go up or down even when no trades are reported?

Morning Brew Icon
China's One Ocean Problem
Date
Direction
Shares
Fund Weight
Fund
February 3, 2022		SELL1.597k0.0002%ARKK
February 1, 2022		SELL67.960k0.0102%ARKK
January 31, 2022		SELL80.005k0.0128%ARKK
January 27, 2022		SELL83.963k0.0133%ARKK
January 26, 2022		SELL1.220m0.1948%ARKK

Key Statistics

⚖️Weighting🧢Market Cap
0%$1.11b
🏋🏿‍♂️Weight Rank In ARKK🌏Country
40🇺🇸United States
🏋️‍♀️Weight Rank Across All Funds💳ARK Estimated Cost Average
137$29.07
Description
As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Website
www.editasmedicine.com

Research Notes and Commentary for EDIT